NCCN Guidelines® Insights: Bladder cancer, version 5.2018: Featured updates to the NCCN Guidelines Journal Article
| Authors: | Flaig, T. W.; Spiess, P. E.; Agarwal, N.; Bangs, R.; Boorjian, S. A.; Buyyounouski, M. K.; Downs, T. M.; Efstathiou, J. A.; Friedlander, T.; Greenberg, R. E.; Guru, K. A.; Hahn, N.; Herr, H. W.; Hoimes, C.; Inman, B. A.; Jimbo, M.; Kader, A. K.; Lele, S. M.; Meeks, J. J.; Michalski, J.; Montgomery, J. S.; Pagliaro, L. C.; Pal, S. K.; Patterson, A.; Petrylak, D. P.; Plimack, E. R.; Pohar, K. S.; Porter, M. P.; Preston, M. A.; Sexton, W. J.; Siefker-Radtke, A. O.; Tward, J.; Wile, G.; Johnson-Chilla, A.; Dwyer, M. A.; Gurski, L. A. |
| Article Title: | NCCN Guidelines® Insights: Bladder cancer, version 5.2018: Featured updates to the NCCN Guidelines |
| Abstract: | The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease. © JNCCN—Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 16 |
| Issue: | 9 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2018-09-01 |
| Start Page: | 1041 |
| End Page: | 1053 |
| Language: | English |
| DOI: | 10.6004/jnccn.2018.0072 |
| PROVIDER: | scopus |
| PUBMED: | 30181416 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 October 2018 -- Source: Scopus |
